Mode
Text Size
Log in / Sign up
N/A N=77 Randomized Double-blind Other

Study of Growth Hormone and Bone in Obesity

Obesity · Osteopenia

Enrolled (actual)
77
Serious AEs
1.3%
Results posted
Dec 2019
Primary outcome: Primary: Bone Mineral Density — -0.015; -0.008 grams/cm^2

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Growth hormone (Drug); Placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Massachusetts General Hospital
Primary completion
Nov 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Bone Mineral Density
-0.015; -0.008

Summary

Obesity is an important risk factor for osteoporosis and fractures. With the growing prevalence of obesity in the U.S., understanding the pathophysiology of bone loss in this population is of importance to public health. Growth hormone (GH) is a critical mediator of bone homeostasis and is markedly reduced in obesity. Our preliminary data suggest an important role for the GH/insulin-like growth factor 1 (IGF-1) system in the pathogenesis of bone loss in obesity. The development of novel imaging techniques provides an opportunity to investigate the effects of GH on skeletal structure and strength, which will provide insights into the pathogenesis of obesity related bone loss. Understanding the pathophysiology of bone loss in obesity may help identify new treatment targets for this important complication. The investigator hypothesizes that low-dose GH administration for 18 months will improve skeletal health.

Eligibility Criteria

Inclusion Criteria

  • Ages 18-65 and generally healthy
  • BMI ≥ 25 kg/m2
  • Bone mineral density (BMD) T score ≤ -1.0 and > -2.5 (as measured by DXA)

Exclusion Criteria

  • For women: amenorrhea for 3 months, pregnancy or breastfeeding, polycystic ovary syndrome
  • History of diabetes mellitus, cancer or other serious chronic disease
  • Use of osteoporosis medications
  • Anemia
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01724489). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search